You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 29, 2024

CLINICAL TRIALS PROFILE FOR GLIPIZIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Glipizide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00094770 ↗ An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024) Completed Merck Sharp & Dohme Corp. Phase 3 2004-09-01 The purpose of this investigational study is to determine the safety and effectiveness of an investigational drug in patients with type 2 diabetes mellitus (a specific type of diabetes).
NCT00095056 ↗ An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED) Completed Merck Sharp & Dohme Corp. Phase 3 2004-10-01 The purpose of this study is to determine the safety and tolerability of an investigational drug in patients with Type 2 Diabetes Mellitus (a specific type of diabetes) and Chronic Renal Insufficiency (inadequate kidney function).
NCT00116831 ↗ Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes Completed GlaxoSmithKline Phase 3 2005-01-01 The purpose of this study is to test the safety and effectiveness of rosiglitazone against a sulfonylurea in reducing or slowing the development of atherosclerosis in the blood vessels of the heart.
NCT00347100 ↗ Insulin Glargine in Type 2 Diabetic Patients Completed Sanofi Phase 4 2006-06-01 Primary: - To investigate the efficacy of insulin glargine (in terms of change in A1c from baseline to endpoint A1c < 7%) Secondary: - To investigate the safety of insulin glargine (in terms of hypoglycaemia, including symptomatic, non-symptomatic and nocturnal hypoglycaemia) - To investigate whether beta cell function is preserved if this therapy is initiated before 2nd OAD (oral anti-diabetic drug) failure
NCT00350779 ↗ Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052) Completed Merck Sharp & Dohme Corp. Phase 3 2006-06-12 A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin/peroxisome proliferator-activated receptor gamma (PPARg) agonist combination therapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Glipizide

Condition Name

Condition Name for Glipizide
Intervention Trials
Diabetes Mellitus, Type 2 9
Type 2 Diabetes 8
Type 2 Diabetes Mellitus 8
Healthy 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Glipizide
Intervention Trials
Diabetes Mellitus 28
Diabetes Mellitus, Type 2 25
Renal Insufficiency, Chronic 5
Kidney Diseases 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Glipizide

Trials by Country

Trials by Country for Glipizide
Location Trials
United States 92
India 18
Mexico 17
Germany 14
Italy 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Glipizide
Location Trials
North Dakota 6
Illinois 5
California 5
Texas 5
Pennsylvania 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Glipizide

Clinical Trial Phase

Clinical Trial Phase for Glipizide
Clinical Trial Phase Trials
Phase 4 11
Phase 3 13
Phase 2 2
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Glipizide
Clinical Trial Phase Trials
Completed 32
Unknown status 4
Terminated 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Glipizide

Sponsor Name

Sponsor Name for Glipizide
Sponsor Trials
Merck Sharp & Dohme Corp. 11
Canadian Institutes of Health Research (CIHR) 3
Drug Safety and Effectiveness Network, Canada 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Glipizide
Sponsor Trials
Other 30
Industry 29
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.